

Список публикаций

Вадим А. Макаров

Web of Science Research ID AAE-5483-2021

Scopus Author ID 74016900520

ORCID 0000-0001-8746-2694

НАУЧНЫЕ СТАТЬИ И ОБЗОРЫ

1991-1999

1. Nemeryuk MP, Sedov AL, **Makarov VA**, Safonova TS. Conversion of 4-chloro-5-nitropyrimidines to 1,3,5-triazines using alkylisothiureas. Chem Heterocycl Compd. 1991; 27; 804-805. doi: 10.1007/BF00476222.
2. **Makarov VA**, Sedov AL, Nemeryuk MP, Safonova TS. Reactions of 4(6)-chloro-5-nitropyrimidines with nucleophilic agents (review). Pharm Chem J. 1993; 27: 245-254. doi: 10.1007/BF00810974.
3. **Makarov VA**, Sedov AL, Nemeryuk MP, Solov'eva NP, Safonova TS. Highly polarized enamines 1. synthesis and some properties of β -tetrazolylenamines. Chem Heterocycl Compd. 1994; 30: 8406-850. doi: 10.1007/BF01169644.
4. **Makarov VA**, Sedov AL, Nemeryuk MP, Safonova TS. Investigation of bis-heteryl derivatives of piperazine and its analogs 1. Synthesis and conversions of *N,N'*-bis(2-*R*-5-nitro-6-pyrimidinyl)piperazines and *N,N*³-bis(2-*R*-5-nitro-6-pyrimidinyl)dispiro-tripiperazinium dichloride. Chem Heterocycl Compd. 1994; 30: 841-845. doi: 10.1007/BF01169643.
5. **Makarov VA**, Sedov AL, Nemeryuk MP, Solov'eva NP, Anisimova OS, Safonova TS. 4-Dialkyldithiocarbamoyl-5-nitropyrimidines. Synthesis, structure, properties. Chem Heterocycl Compd. 1994; 30: 1231-1234. doi: 10.1007/BF01184891.
6. **Makarov VA**, Sedov AL, Nemeryuk MP, Solov'eva NP, Anisimova OS, Safonova TS. Investigation of bisheteryl derivatives of piperazine and its analogs. 2. Synthesis and properties of bis(dialkyldithiocarbamoyl-5-nitro-4-pyrimidyl)piperazines. Chem Heterocycl Compd. 1995; 31: 181-182. doi: 10.1007/BF01169676.
7. **Makarov VA**, Sedov AL, Anisimova OS, Granik VG. Highly polarized enamines. 2. Synthesis and investigation of the further amination of derivatives of α,α -diamino- β -cyano- β -nitroethylene. Chem Heterocycl Compd. 1996; 32: 699-707. doi: 10.1007/BF01164870.
8. Solov'eva NP, **Makarov VA**, Granik VG. Highly polarized enamines. 3. Study of the spatial structure of α,α -diamino- β -cyano- β -nitroethylene derivatives. Chem Heterocycl Compd. 1997; 33: 78-85. doi: 10.1007/BF02290751.

9. **Makarov VA**, Tafeenko VA, Granik VG. Highly polarized enamines. 2. Unusual transformation of α,α -diamino- β -cyano- β -nitroethylene derivatives into 4,6-bisdimethylamino-5-nitropyrimidine. *Chem Heterocycl Compd.* 1997; 33: 288-292. doi: 10.1007/BF02253108.
10. **Makarov VA**, Anisimova OS, Granik VG. Reaction of 3,5-diamino-4-nitropyrazole with electrophilic reagents. *Chem Heterocycl Compd.* 1997; 33: 276-281. doi: 10.1007/BF02253106.
11. **Makarov VA**, Solov'eva NP, Granik VG. Synthesis and NMR spectroscopic study of derivatives of pyrazolo[1,5-*a*]pyrimidines. *Chem Heterocycl Compd.* 1997; 33: 535-542. doi: 10.1007/BF02291935.
12. **Makarov VA**, Granik VG. Synthesis and properties of β,β -bisfunctionalised ketene *N,N*-acetals. *Russ Chem Rev.* 1998; 67: 923-940. doi: 10.1070/RC1998v067n11ABEH000422.
13. Granik VG, **Makarov VA**, Parkaniy C. Enamines as synthons in the synthesis of heterocycles (review). *Adv. Heterocycl. Chem.* 1998; 72: 283-358. doi: 10.1016/S0065-2725(08)60318-9.
14. Chernyshev VV, Yatsenko AV, Tafeenko VA, Zhukov SG, Aslanov LA, Sonneveld EJ, Schenk H, **Makarov VA**, Granik VG, Trounov VA, Kurbakov AI. Crystal structures of pyrazolo[1,5-*a*]pyrimidine derivatives solved from powder diffraction data. *Z Kristallogr Cryst Mater.* 1998; 213(9): 477-482. doi: 10.1524/zkri.1998.213.9.477
15. **Makarov VA**, Tafeenko VA, Granik VG. Synthesis of pyrazolo[1,5-*a*]pyrimidines by the reaction of β -dicarbonyl compounds with 3,5-diamino-4-nitropyrazole. *Chem Heterocycl Compd.* 1998; 34: 1423-1427. doi: 10.1007/BF02317814.
16. Chernyshev VV, Yatsenko AY, Tafeenko VA, **Makarov VA**, Sonneveld EJ, Schenk H. 3,12-Diaza-6,9-diazoniadispiro[5,2,5,2]hexadecane dichloride from X-ray powder data, *Acta Cryst. C.* 1999; C55: 1099-1101. doi: 10.1107/S0108270199004138.
17. Chernyshev VV, Fitch AN, Sonneveld EJ, Kurbakov AI, **Makarov VA**, Tafeenko VA. Crystal and molecular structures of 2-[1-(2-aminoethyl)-2-imidazolidinylidene]-2-nitroacetonitrile ($C_7H_{11}N_5O_2$) and 2,6-diamino-5-hydroxy-3-nitro-4H-pyrazolo[1,5-*a*]pyrimidin-7-one monohydrate ($C_6H_6N_6O_4 \cdot H_2O$) from X-ray, synchrotron and neutron powder diffraction data. *Acta Crystallogr B.* 1999; 55(Pt4): 554-562. doi: 10.1107/s010876819900213x.
18. Chernyshev VV, Yatsenko AV, Tafeenko VA, Sonneveld EJ, Schenk H, **Makarov VA**. Crystal and molecular structure of 1-amino-4-methoxycarbonyl-3-methyl-8-oxopyrazolo[1,5-*a*]pyrimidine monohydrate from laboratory powder data. *Powder Diffraction.* 1999; 14: 289-292. doi: 10.1017/S0885715600010708.

2000-2008

19. **Makarov VA**, Solov'eva NP, Chernyshev VV, Sonneveld EJ, Granik VG. Study of the reaction of 3,5-diamino-4-carbomethoxy-pyrazole with acetoacetic ester. Synthesis of

- pyrazolo[1,5-*a*]pyrimidine. Chem Heterocycl Compd. 2000; 36: 70-73. doi: 10.1007/BF02256848.
20. **Makarov VA**, Solov'eva NP, **Ryabova OB**, Granik VG. Synthesis of pyrazolo[1,5-*a*]pyrimidines by reaction of 3,5-diamino-4-nitropyrazole with acetoacetic ester in the presence of alkaline agents. Chem Heterocycl Compd. 2000; 36: 65-69. doi: 10.1007/BF02256847.
21. Chernyshev VV, Tafeenko VA, **Makarov VA**, Sonneveld EJ, Schenk H, 3,5-Bis[*N,N*-dimethylamino)methyleneamino]-1-methyl-4-nitropyrazole from X-ray powder diffraction data. Acta Cryst. C. 2000; C56: 1159-1160. doi: 10.1107/S010827010000860X.
22. Chernyshev VV, Paseshnichenko KA, **Makarov VA**, Sonneveld EJ, Schenk H. Metabolic pathways of dithiocarbamates from laboratory powder diffraction data. Acta Crystallogr C. 2001; 57(Pt 1): 72-75. doi: 10.1107/s0108270100013457.
23. Schmidtke M, **Ryabova O**, Dahse HM, Stelzner A, **Makarov V**. Synthesis, cytotoxicity and antiviral activity of *N,N'*-bis-5-nitropyrimidyl derivatives of dispirotriperazine. Antiviral Res. 2002; 55(1): 117-127. doi: 10.1016/s0166-3542(02)00014-1.
24. **Makarov VA**, **Ryabova OB**, Alekseeva LM, Chernyshev VV, Granik VG. Investigation of the reaction of 3,5-diamidino-4-nitropyrazole with amines. Chem Heterocycl Compd. 2002; 38: 947-953. doi: 10.1023/A:1020921530209.
25. Granik VG, Kaminka M^É, Grigor'ev NB, Severina IS, Kalinkina MA, **Makarov VA**, Levina VI. Furoxanopyrimidines as exogenous donors of nitric oxide. Pharm Chem J. 2002; 36: 523-527. doi: 10.1023/A:1022446208137.
26. **Makarov VA**, Danilov AV, Levina VI, Grigoriev NB, Schmidtke M, Stelzner A, Granik VG. 4-Nitropyrazole derivatives as new exogenic donors of nitric oxide. Prob Biol Med Pharm Chem. 2002; 6: 45-50. [In Russian].
27. Tafeenko VA, Chernyshev VV, Yatsenko AV, **Makarov VA**, Sonneveld EJ, Peschar R, Schenk H. Intermolecular -CH₃...O₂N- contacts in two polymorphic modifications of (1*E*)-*N'*-[(*E*)-2-cyano-1-(dimethylamino)-2-nitrovinyl]-*N,N*-dimethylethanimidamide. Acta Crystallogr B. 2003; 59(Pt 4): 492-497. doi: 10.1107/s0108768103010231.
28. **Makarov VA**, **Ryabova OB**, Alekseeva LM, Shashkov AS, Granik VG. Synthesis of derivatives of pyrazolo[3,4-*d*]pyrimidines by reaction of 3,5-bis(dimethylaminomethylene)amino-4-methoxycarbonylpyrazole and 4-cyanopyrazole with amines. Chem Heterocycl Comp. 2003; 39: 238-243. doi: 10.1023/A:1023780710982.
29. Schmidtke M, Karger A, Meerbach A, Egerer R, Stelzner A, **Makarov V**. Binding of a *N,N'*-bisheteryl derivative of dispirotriperazine to heparan sulfate residues on the cell surface specifically prevents infection of viruses from different families. Virology. 2003; 311(1): 134-143. doi: 10.1016/s0042-6822(03)00166-1.

30. **Riabova OB, Makarov VA**, Chernishev VV, Granik VG. Synthesis and thermal transformation of 5-nitropyrimidin-4-yl dialkyldithiocarbamates. Russ Chem Bull. 2004; 53: 882-888. doi: B:RUCB.0000037858.17011.fb.
31. Kaminka ME, Kalinkina MA, Pushkina TV, Tupikina SM, **Riabova OB, Makarov VA**, Granik VG. Antiulcer activity of furoxanopyrimidine derivatives. Eksp Klin Farmakol. 2004; 67(3): 30-33. [In Russian].
32. **Ryabova OB**, Evstratova MI, **Makarov VA**, Tafeenko VA, Granik VG. New method for the synthesis of thieno[2,3-*d*]pyrimidines. Chem Heterocycl Compd. 2004; 40: 1352-1358. doi: 10.1007/s10593-005-0018-6.
33. Schmidtke M, Wutzler P, **Makarov V**. Novel opportunities to study and block interactions between viruses and cell surface heparan sulfates. Lett Drug Design Discov. 2004; 1(4): 35-44. doi: 10.2174/1570180043398768.
34. Chernyshev VV, Stephens PW, Yatsenko AV, **Ryabova OB, Makarov VA**. Structural characterization of prazosin hydrochloride and prazosin free base. J Pharm Sci. 2004; 93(12): 3090-3095. doi: 10.1002/jps.20204.
35. Schmidtke M, Schacke M, Helbig B, Wutzler P, Meier C, **Makarov V**, Rabenau HF, Cinatl J. Antiviral activity of phenolic polymers and cycloSal-pronucleotides against a SARS-associated coronavirus. Chemotherapie Journal. 2005; 14: 16-21.
36. **Makarov VA, Riabova OB**, Granik VG, Dahse HM, Stelzner A, Wutzler P, Schmidtke M. Anti-coxsackievirus B3 activity of 2-amino-3-nitropyrazolo[1,5-*a*]pyrimidines and their analogs. Bioorg Med Chem Lett. 2005; 15(1): 37-39. doi: 10.1016/j.bmcl.2004.10.043.
37. **Makarov VA, Riabova OB**, Granik VG, Wutzler P, Schmidtke M. Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J Antimicrob Chemother. 2005; 55(4): 483-488. doi: 10.1093/jac/dki055.
38. **Ryabova OB, Makarov VA**, Alekseeva LM, Shashkov AS, Chernyshev VV, Granik VG. Transformations of *ortho*-methoxyaryl(hetaryl)carboxamides into quinazolin-4-one and pyrido[2,3-*d*]pyrimidin-4-one derivatives. Russ Chem Bull. 2005; 54(8): 1907-1914. doi: 10.1007/s11172-006-0057-x.
39. Schmidtke M, Hammerschmidt E, Schüler S, Zell R, Birch-Hirschfeld E, **Makarov VA, Riabova OB**, Wutzler P. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother. 2005; 56(4): 648-656. doi: 10.1093/jac/dki263.
40. **Ryabova OB**, Khmel'nitskaya EY, **Makarov VA**, Alekseeva LM, Grigoriev NB, Granik VG. 4-(*N,N*-Dialkylthiocarbamoylthio)-5-nitropyrimidines as new potential nitric oxide donors. Russ Chem Bull. 2005; 54(12): 2873-2879. doi: 10.1007/s11172-006-0203-5.

41. **Komarova ES, Makarov VA**, Alekseeva LM, Avramenko GV, Granik VG. Synthesis of derivatives of a new heterocyclic system pyrazolo[3,4-*b*]pyrido[1',2': 1,2]imidazo[4,5-*d*]pyridine. *Russ Chem Bull.* 2006; 55(4): 735-740. doi: 10.1007/s11172-006-0322-z.
42. **Makarov V, Riabova OB**, Yuschenko A, Urlyapova N, Daudova A, Zipfel PF, Möllmann U. Synthesis and antileprosy activity of some dialkyldithiocarbamates. *J Antimicrob Chemother.* 2006; 57(6): 1134-1138. doi: 10.1093/jac/dkl095.
43. Urlyapova NG, Yushchenko AA, Daudova AD, **Makarov VA**. Study of antileprosy activities of some dialkyldithiocarbamate derivatives. *Bull Exp Biol Med.* 2007; 143: 356-358. doi: 10.1007/s10517-007-0111-1.
44. Artemenko AG, Muratov EN, Kuz'min VE, Kovdienko NA, Hromov AI, **Makarov VA, Riabova OB**, Wutzler P, Schmidtke M. Identification of individual structural fragments of *N,N'*-(bis-5-nitropyrimidyl)dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. *J Antimicrob Chemother.* 2007; 60(1): 68-77. doi: 10.1093/jac/dkm172.
45. Kuz'min VE, Artemenko AG, Muratov EN, Volineckaya IL, **Makarov VA, Riabova OB**, Wutzler P, Schmidtke M. Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. *J Med Chem.* 2007; 50(17): 4205-4213. doi: 10.1021/jm0704806.
46. Selinka HC, Florin L, Patel HD, Freitag K, Schmidtke M, **Makarov VA**, Sapp M. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. *J Virol.* 2007; 81(20): 10970-10980. doi: 10.1128/JVI.00998-07.
47. **Komarova ES, Makarov VA**, Alekseeva LM, Avramenko GV, Granik VG. 4,5-Diamino-1-phenyl-1,7-dihydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one in the synthesis of fused tricyclic systems. *Russ Chem Bull.* 2007; 56: 2337-2343. doi: 10.1007/s11172-007-0369-5.
48. Urlyapova NG, Yuschenko AA, Daudova AD, **Makarov VA**. Antileprosy activity and preliminary toxicological characteristics of some dialkyldithiocarbamate derivatives. *Bull Exp Biol Med.* 2008; 145: 446-448. doi: 10.1007/s10517-008-0114-6.
49. **Riabova OB, Makarov VA**, Granik VG, Parkanyi C. Transformations of 5-nitropyrimidines. *J Heterocycl Chem.* 2008; **45**(3): 621-643. DOI: 10.1002/jhet.5570450301.
50. Wegener D, Hildmann C, Riester D, Schober A, Meyer-Almes FJ, Deubzer HE, Oehme I, Witt O, Lang S, Jaensch M, **Makarov V**, Lange C, Busse B, Schwienhorst A. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorogenic assay. *Biochem J.* 2008; 413(1): 143-150. DOI: 10.1042/BJ20080536.

2009

51. Schmidtke M, Wutzler P, Zieger R, **Riabova OB, Makarov VA**. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit

- antiviral activity against pleconaril-resistant coxsackievirus B3. *Antiviral Res.* 2009; 81(1): 56-63. DOI: 10.1016/j.antiviral.2008.09.002.
52. **Makarov V**, Manina G, Mikusova K, Möllmann U, **Ryabova O**, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesht T, Tyagi S, Grosset J, Riccardi G, Cole ST. Benzothiazinones kill *Mycobacterium tuberculosis* by blocking arabinan synthesis. *Science.* 2009; 324(5928): 801-804. DOI: 10.1126/science.1171583.
53. Demina GR, **Makarov VA**, Nikitushkin VD, **Ryabova OB**, Vostroknutova GN, Salina EG, Shleeva MO, Goncharenko AV, Kaprelyants AS. Finding of the low molecular weight inhibitors of resuscitation promoting factor enzymatic and resuscitation activity. *PLoS One.* 2009; 4(12): e8174. DOI: 10.1371/journal.pone.0008174.

2010

54. Pasca MR, Degiacomi G, Ribeiro AL, Zara F, De Mori P, Heym B, Mirrione M, Berra R, Pagani L, Pucillo L, Troupioti P, **Makarov V**, Cole ST, Riccardi G. Clinical isolates of *Mycobacterium tuberculosis* in four European hospitals are uniformly susceptible to benzothiazinones. *Antimicrob Agents Chemother.* 2010; 54(4): 1616-1618. DOI: 10.1128/AAC.01676-09.
55. Muratov EN, Artemenko AG, Varlamova EV, Polischuk PG, Lozitsky VP, Fedchuk AS, Lozitska RL, Gridina TL, Koroleva LS, Sil'nikov VN, Galabov AS, **Makarov VA**, **Riabova OB**, Wutzler P, Schmidtke M, Kuz'min VE. Per aspera ad astra: application of Simplex QSAR approach in antiviral research. *Future Med Chem.* 2010; 2(7): 1205-1226. DOI: 10.4155/fmc.10.194.
56. Manina G, Bellinzoni M, Pasca MR, Neres J, Milano A, Ribeiro AL, Buroni S, Skovierová H, Dianišková P, Mikušová K, Marák J, **Makarov V**, Giganti D, Haouz A, Lucarelli AP, Degiacomi G, Piazza A, Chiarelli LR, De Rossi E, Salina E, Cole ST, Alzari PM, Riccardi G. Biological and structural characterization of the *Mycobacterium smegmatis* nitroreductase NfnB, and its role in benzothiazinone resistance. *Mol Microbiol.* 2010; 77(5): 1172-1185. DOI: 10.1111/j.1365-2958.2010.07277.x.
57. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, **Makarov V**, Cole ST, Johnsson K. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl- β -D-ribose 2'-epimerase DprE1 of *Mycobacterium tuberculosis*. *J Am Chem Soc.* 2010; 132(39): 13663-13665. DOI: 10.1021/ja106357w.

2011

58. Muratov EN, Varlamova EV, Artemenko AG, Khristova T, Kuz'min VE, **Makarov VA**, **Riabova OB**, Wutzler P, Schmidtke M. QSAR analysis of [(biphenyloxy)propyl]isoxazoles:

agents against coxsackievirus B3. *Future Med Chem.* 2011; 3(1): 15-27. DOI: 10.4155/fmc.10.278.

2012

59. Trefzer C, Škovierová H, Buroni S, Bobovská A, Nenci S, Molteni E, Pojer F, Pasca MR, **Makarov V**, Cole ST, Riccardi G, Mikušová K, Johnsson K. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl- β -D-ribofuranose 2'-oxidase DprE1. *J Am Chem Soc.* 2012; 134(2): 912-915. DOI: 10.1021/ja211042r.
60. **Komarova E**, **Makarov V**, Granik V, Párkányi C. Synthesis of pyrazolo[3,4-b]pyridine-6-ones. *J Heterocycl Chem.* 2012; 4(5): 969-998. DOI: 10.1002/jhet.986.
61. Kaprelyants AS, Mukamolova GV, Ruggiero A, **Makarov VA**, Demina GR, Shleeva MO, Potapov VD, Shramko PA. Resuscitation-promoting factors (Rpf): in search of inhibitors. *Protein Pept Lett.* 2012; 19(10): 1026-1034. DOI: 10.2174/092986612802762723.

2013

62. Ruggiero A, Marchant J, Squeglia F, **Makarov V**, De Simone A, Berisio R. Molecular determinants of inactivation of the resuscitation promoting factor B from *Mycobacterium tuberculosis*. *J Biomol Struct Dyn.* 2013; 31(2): 195-205. DOI: 10.1080/07391102.2012.698243.
63. Knop K, Pavlov GM, Rudolph T, Martin K, Pretzel D, Jahn BO, Scharf DH, Brakhage AA, **Makarov V**, Mollmann U, Schacher FH, Schubert US. Amphiphilic star-shaped block copolymers as unimolecular drug delivery systems: investigations using a novel fungicide. *Soft Matter.* 2013; 9 : 715-726. DOI: 10.1039/c2sm26509e.

2014

64. Mikusová K, **Makarov V**, Neres J. DprE1 — from the discovery to the promising tuberculosis drug target. *Curr Pharm Des.* 2014; 20(27): 4379-403. DOI: 10.2174/138161282027140630122724.
65. Salina E, **Ryabova O**, Kaprelyants A, **Makarov V**. New 2-thiopyridines as potential candidates for killing both actively growing and dormant *Mycobacterium tuberculosis* cells. *Antimicrob Agents Chemother.* 2014; 58(1): 55-60. DOI: 10.1128/AAC.01308-13.
66. Hartkoorn RC, **Ryabova OB**, Chiarelli LR, Riccardi G, **Makarov V**, Cole ST. Mechanism of action of 5-nitrothiophenes against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* 2014; 58(5): 2944-2947. DOI: 10.1128/AAC.02693-13.
67. **Makarov V**, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, **Ryabova OB**, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. *EMBO Mol Med.* 2014; 6(3): 372-383. DOI: 10.1002/emmm.201303575.
68. Paeschke R, Woskobojsnik I, **Makarov V**, Schmidtke M, Bogner E. DSTP-27 prevents entry of human cytomegalovirus. *Antimicrob Agents Chemother.* 2014; 58(4): 1963-1971. DOI: 10.1128/AAC.01964-13.

69. Scoffone VC, Spadaro F, Udine C, Makarov V, Fondi M, Fani R, De Rossi E, Riccardi G, Buroni S. Mechanism of resistance to an antitubercular 2-thiopyridine derivative that is also active against *Burkholderia cenocepacia*. *Antimicrob Agents Chemother*. 2014; 58(4): 2415-2417. DOI: 10.1128/AAC.02438-13.
70. Albesa-Jové D, Chiarelli LR, **Makarov V**, Pasca MR, Urresti S, Mori G, Salina E, Vocat A, Comino N, Mohorko E, **Ryabova S**, Pfeiffer B, Lopes Ribeiro AL, Rodrigo-Unzueta A, Tersa M, Zanoni G, Buroni S, Altmann KH, Hartkoorn RC, Glockshuber R, Cole ST, Riccardi G, Guerin ME. Rv2466c mediates the activation of TP053 to kill replicating and non-replicating *Mycobacterium tuberculosis*. *ACS Chem Biol*. 2014; 9(7): 1567-1575. DOI: 10.1021/cb500149m.
71. Turapov O, Glenn S, Kana B, **Makarov V**, Andrew PW, Mukamolova GV. The *in vivo* environment accelerates generation of resuscitation-promoting factor-dependent mycobacteria. *Am J Respir Crit Care Med*. 2014; 190(12): 1455-1457. DOI: 10.1164/rccm.201407-1289LE.

2015

72. Neres J, Hartkoorn RC, Chiarelli LR, Gadupudi R, Pasca MR, Mori G, Venturelli A, **Savina S**, **Makarov V**, Kolly GS, Molteni E, Binda C, Dhar N, Ferrari S, Brodin P, Delorme V, Landry V, de Jesus Lopes Ribeiro AL, Farina D, Saxena P, Pojer F, Carta A, Luciani R, Porta A, Zanoni G, De Rossi E, Costi MP, Riccardi G, Cole ST. 2-Carboxyquinoxalines kill *Mycobacterium tuberculosis* through noncovalent inhibition of DprE1. *ACS Chem Biol*. 2015; 10(3): 705-714. DOI: 10.1021/cb5007163.
73. **Makarov V**, Neres J, Hartkoorn RC, **Ryabova OB**, **Kazakova E**, Šarkan M, Huszár S, Piton J, Kolly GS, Vocat A, Conroy TM, Mikušová K, Cole ST. The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2015; 59(8): 4446-4452. DOI: 10.1128/AAC.00778-15.
74. Mori G, Chiarelli LR, Esposito M, **Makarov V**, Bellinzoni M, Hartkoorn RC, Degiacomi G, Boldrin F, Ekins S, de Jesus Lopes Ribeiro AL, Marino LB, Centárová I, Svetlíková Z, Blaško J, **Kazakova E**, **Lepioshkin A**, Barilone N, Zanoni G, Porta A, Fondi M, Fani R, Baulard AR, Mikušová K, Alzari PM, Manganelli R, de Carvalho LP, Riccardi G, Cole ST, Pasca MR. Thiophenecarboxamide derivatives activated by EthA kill *Mycobacterium tuberculosis* by inhibiting the CTP synthetase PyrG. *Chem Biol*. 2015; 22(7): 917-927. DOI: 10.1016/j.chembiol.2015.05.016.
75. Scoffone VC, **Ryabova O**, **Makarov V**, Iadarola P, Fumagalli M, Fondi M, Fani R, De Rossi E, Riccardi G, Buroni S. Efflux-mediated resistance to a benzothiadiazol derivative effective against *Burkholderia cenocepacia*. *Front Microbiol*. 2015; 6: 815. DOI: 10.3389/fmicb.2015.00815.
76. González-Martínez NA, Lozano-Garza HG, Castro-Garza J, De Osio-Cortez A, Vargas-Villarreal J, Cavazos-Rocha N, Ocampo-Candiani J, **Makarov V**, Cole ST, Vera-Cabrera L.

- In vivo* activity of the benzothiazinones PBTZ169 and BTZ043 against *Nocardia brasiliensis*. PLoS Negl Trop Dis. 2015; 9(10): e0004022. DOI: 10.1371/journal.pntd.0004022.
77. **Makarov VA**, Braun H, Richter M, **Riabova OB**, Kirchmair J, **Kazakova ES**, Seidel N, Wutzler P, Schmidtke M. Pyrazolopyrimidines: potent inhibitors targeting the capsid of rhino- and enteroviruses. ChemMedChem. 2015; 10(10): 1629-1634. DOI: 10.1002/cmdc.201500304.
78. Braun H, Kirchmair J, Williamson MJ, **Makarov VA**, **Riabova OB**, Glen RC, Sauerbrei A, Schmidtke M. Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket. Antiviral Res. 2015; 123: 138-145. doi: 10.1016/j.antiviral.2015.09.009.
79. Albesa-Jové D, Comino N, Tersa M, Mohorko E, Urresti S, Dainese E, Chiarelli LR, Pasca MR, Manganelli R, **Makarov V**, Riccardi G, Svergun DI, Glockshuber R, Guerin ME. The redox state regulates the conformation of Rv2466c to activate the antitubercular prodrug TP053. J Biol Chem. 2015; 290(52): 31077-31089. DOI: 10.1074/jbc.M115.677039.

2016

80. **Monakhova N**, **Ryabova S**, **Makarov V**. Synthesis and biological properties of pyrrolo[1,2-*a*]indoles. J Heterocycl Chem. 2016; 53(3): 685-709. DOI:10.1002/jhet.2312.
81. Grienke U, Richter M, Walther E, Hoffmann A, Kirchmair J, **Makarov V**, Nietzsche S, Schmidtke M, Rollinger JM. Discovery of prenylated flavonoids with dual activity against influenza virus and *Streptococcus pneumoniae*. Sci Rep. 2016; 6: 27156. DOI: 10.1038/srep27156.
82. Scoffone VC, Chiarelli LR, **Makarov V**, Brackman G, Israyilova A, Azzalin A, Forneris F, **Riabova O**, **Savina S**, Coenye T, Riccardi G, Buroni S. Discovery of new diketopiperazines inhibiting *Burkholderia cenocepacia* quorum sensing *in vitro* and *in vivo*. Sci Rep. 2016; 6: 32487. DOI: 10.1038/srep32487.
83. Grienke U, Richter M, Walther E, Hoffmann A, Kirchmair J, **Makarov V**, Nietzsche S, Schmidtke M, Rollinger JM. Killing two birds with one stone - Prenylated flavonoids disrupt the lethal synergism of influenza A viruses and pneumococci. Planta Med. 2016; 82(S 01): S1-S381. DOI: 10.1055/s-0036-1596116.

2017

84. **Novoselova EA**, **Riabova OB**, Leneva IA, Nesterenko VG, Bolgarin RN, **Makarov VA**. Antiretroviral activity of a novel pyrimidyl-di(diazaspiroalkane) derivative. Acta Naturae. 2017; 9(1): 105-107. DOI: 10.32607/20758251-2017-9-1-105-107.
85. Salina EG, **Ryabova O**, Vocat A, Nikonenko B, Cole ST, Makarov **V**. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis. J Infect Chemother. 2017; 23(11): 794-797. DOI: 10.1016/j.jiac.2017.04.012.

86. Smith LJ, Bochkareva A, Rolfe MD, Hunt DM, Kahramanoglou C, Braun Y, Rodgers A, Blockley A, Coade S, Loughheed KEA, Hafneh NA, Glenn SM, Crack JC, Le Brun NE, Saldanha JW, **Makarov V**, Nobeli I, Arnvig K, Mukamolova GV, Buxton RS, Green J. Cmr is a redox-responsive regulator of DosR that contributes to *M. tuberculosis* virulence. *Nucleic Acids Res.* 2017; 45(11): 6600-6612. DOI: 10.1093/nar/gkx406.
87. Rosado LA, Wahni K, Degiacomi G, Pedre B, Young D, de la Rubia AG, Boldrin F, Martens E, Marcos-Pascual L, Sancho-Vaello E, Albesa-Jové D, Provvedi R, Martin C, **Makarov V**, Versées W, Verniest G, Guerin ME, Mateos LM, Manganelli R, Messens J. The antibacterial prodrug activator Rv2466c is a mycothiol-dependent reductase in the oxidative stress response of *Mycobacterium tuberculosis*. *J Biol Chem.* 2017; 292(32): 13097-13110. DOI: 10.1074/jbc.M117.797837.
88. Gengenbacher M, Duque-Correa MA, Kaiser P, Schuerer S, Lazar D, Zedler U, Reece ST, Nayyar A, Cole ST, **Makarov V**, Barry Iii CE, Dartois V, Kaufmann SHE. NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. *Sci Rep.* 2017; 7(1): 8853. DOI: 10.1038/s41598-017-09177-2.
89. Demina GR, Nikitushkin VD, Shleeva MO, **Riabova OB**, **Lepioshkin AY**, **Makarov VA**, Kaprelyants AS. Benzoylphenyl thiocyanates are new, effective inhibitors of the mycobacterial resuscitation promoting factor B protein. *Ann Clin Microbiol Antimicrob.* 2017; 16(1): 69. DOI: 10.1186/s12941-017-0244-7.

2018

90. Chiarelli LR, Mori G, Orena BS, Esposito M, Lane T, de Jesus Lopes Ribeiro AL, Degiacomi G, Zemanová J, Szádocka S, Huszár S, Palčeková Z, Manfredi M, Gosetti F, Lelièvre J, Ballell L, **Kazakova E**, **Makarov V**, Marengo E, Mikusova K, Cole ST, Riccardi G, Ekins S, Pasca MR. A multitarget approach to drug discovery inhibiting *Mycobacterium tuberculosis* PyrG and PanK. *Sci Rep.* 2018; 8(1): 3187. DOI: 10.1038/s41598-018-21614-4.
91. Salina EG, Huszár S, Zemanová J, Keruchenko J, **Riabova O**, **Kazakova E**, Grigorov A, Azhikina T, Kaprelyants A, Mikušová K, **Makarov V**. Copper-related toxicity in replicating and dormant *Mycobacterium tuberculosis* caused by 1-hydroxy-5-R-pyridine-2(1H)-thiones. *Metallomics.* 2018; 10(7): 992-1002. DOI: 10.1039/c8mt00067k.
92. Piton J, Vocat A, Lupien A, Foo CS, **Riabova O**, **Makarov V**, Cole ST. Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* 2018; 62(10): e00681-18. DOI: 10.1128/AAC.00681-18.
93. Buroni S, Scoffone VC, Fumagalli M, **Makarov V**, Cagnone M, Trespidi G, De Rossi E, Forneris F, Riccardi G, Chiarelli LR. Investigating the mechanism of action of diketopiperazines inhibitors of the *Burkholderia cenocepacia* quorum sensing synthase CepI: a site-directed mutagenesis study. *Front Pharmacol.* 2018; 9: 836. DOI: 10.3389/fphar.2018.00836.

94. Lupien A, Vocat A, Foo CS, Blattes E, Gillon JY, **Makarov V**, Cole ST. Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169). *Antimicrob Agents Chemother*. 2018; 62(11): e00840-18. DOI: 10.1128/AAC.00840-18.
95. Hogan AM, Scoffone VC, **Makarov V**, Gislason AS, Tesfu H, Stietz MS, Brassinga AKC, Domaratzki M, Li X, Azzalin A, Biggiogera M, **Riabova O**, **Monakhova N**, Chiarelli LR, Riccardi G, Buroni S, Cardona ST. Competitive fitness of essential gene knockdowns reveals a broad-spectrum antibacterial inhibitor of the cell division protein FtsZ. *Antimicrob Agents Chemother*. 2018; 62(12): e01231-18. DOI: 10.1128/AAC.01231-18.
96. Sommer R, Neres J, Piton J, Dhar N, van der Sar A, Mukherjee R, Laroche T, Dyson PJ, McKinney JD, Bitter W, **Makarov V**, Cole ST. fluorescent benzothiazinone analogues efficiently and selectively label Dpre1 in mycobacteria and actinobacteria. *ACS Chem Biol*. 2018; 13(11): 3184-3192. DOI: 10.1021/acscchembio.8b00790.
97. Салина ЕГ, Киарелли ЛР, Паска МР, Макаров ВА. Тиенопиримидины – новые доноры азота, высокоактивные в отношении *Mycobacterium tuberculosis*. Вестник ЦНИИТ. 2018; 4: 17-22.
98. Карантыш ГВ, Гафиятуллина ГШ, Менджерский АМ, Прокофьев ВН, Жукова МВ, **Макаров ВА**. Влияние виндебурнола на неврологический статус и морфологические изменения в головном мозге крыс в модели экспериментального аллергического энцефаломиелимита. *Современные проблемы науки и образования*. 2018; 1: 84.

2019

99. Salina EG, Ekins S, **Makarov VA**. A rapid method for estimation of the efficacy of potential antimicrobials in humans and animals by agar diffusion assay. *Chem Biol Drug Des*. 2019; 93(6): 1021-1025. DOI: 10.1111/cbdd.13427.
100. Zorn KM, Lane TR, Russo DP, Clark AM, **Makarov V**, Ekins S. Multiple machine learning comparisons of HIV cell-based and reverse transcriptase data sets. *Mol Pharm*. 2019; 16(4): 1620-1632. DOI: 10.1021/acs.molpharmaceut.8b01297.
101. Puhl AC, Garzino Demo A, **Makarov VA**, Ekins S. New targets for HIV drug discovery. *Drug Discov Today*. 2019; 24(5): 1139-1147. DOI: 10.1016/j.drudis.2019.03.013.
102. Spaggiari D, Desfontaine V, Cruchon S, Guinchard S, Vocat A, Blattes E, Pitteloud J, Ciullini L, Bardinet C, Ivanyuk A, **Makarov V**, **Ryabova O**, Buclin T, Cole ST, Decosterd LA. Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma. *PLoS One*. 2019; 14(5): e0217139. DOI: 10.1371/journal.pone.0217139.
103. **Egorova A**, Ekins S, Schmidtke M, **Makarov V**. Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. *Eur J Med Chem*. 2019; 178: 606-622. DOI: 10.1016/j.ejmech.2019.06.008.

104. Wald J, Pasin M, Richter M, Walther C, Mathai N, Kirchmair J, **Makarov VA**, Goessweiner-Mohr N, Marlovits TC, Zanella I, Real-Hohn A, Verdaguer N, Blaas D, Schmidtke M. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site. *Proc Natl Acad Sci U S A*. 2019; 116(38): 19109-19115. DOI: 10.1073/pnas.1904732116.
105. Nunvar J, Hogan AM, Buroni S, **Savina S**, **Makarov V**, Cardona ST, Drevinek P. The effect of 2-thiocyanatopyridine derivative 11026103 on *Burkholderia Cenocepacia*: resistance mechanisms and systemic impact. *Antibiotics (Basel)*. 2019; 8(4): 159. DOI: 10.3390/antibiotics8040159.
106. **Novoselova EA**, **Ryabova OB**, Leneva IA, **Makarov VA**. Specific antiviral activity of pyrimidinedispirotriperazinium alone and in combination with acyclovir on a herpes-simplex-virus infection model. *Pharm Chem J*. 2019; 53: 781–785 DOI: 10.1007/s11094-019-02079-9.
107. Degiacomi G, Sammartino JC, Chiarelli LR, **Riabova O**, **Makarov V**, Pasca MR. *Mycobacterium abscessus*, an emerging and worrisome pathogen among cystic fibrosis patients. *Int J Mol Sci*. 2019; 20(23): 5868. DOI: 10.3390/ijms20235868.

2020

108. Costabile G, Provenzano R, Azzalin A, Scoffone VC, Chiarelli LR, Rondelli V, Grillo I, Zinn T, **Lepioshkin A**, **Savina S**, Miro A, Quaglia F, **Makarov V**, Coenye T, Brocca P, Riccardi G, Buroni S, Ungaro F. PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against *Burkholderia cenocepacia* infection. *Nanomedicine*. 2020; 23: 102113. DOI: 10.1016/j.nano.2019.102113.
109. Lupien A, Foo CS, **Savina S**, Vocat A, Piton J, **Monakhova N**, Benjak A, Lamprecht DA, Steyn AJC, Pethe K, **Makarov VA**, Cole ST. New 2-ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in *Mycobacterium tuberculosis*. *PLoS Pathog*. 2020; 16(1): e1008270. DOI: 10.1371/journal.ppat.1008270.
110. **Egorova A**, **Kazakova E**, Jahn B, Ekins S, **Makarov V**, Schmidtke M. Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. *Eur J Med Chem*. 2020; 188: 112007. DOI: 10.1016/j.ejmech.2019.112007.
111. Chiarelli LR, Salina EG, Mori G, Azhikina T, **Riabova O**, **Lepioshkin A**, Grigorov A, Forbak M, Madacki J, Orena BS, Manfredi M, Gosetti F, Buzzi A, Degiacomi G, Sammartino JC, Marengo E, Korduláková J, Riccardi G, Mikušová K, **Makarov V**, Pasca MR. New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053. *ACS Infect Dis*. 2020; 6(2): 313-323. DOI: 10.1021/acsinfecdis.9b00388.
112. Buroni S, **Makarov V**, Scoffone VC, Trespidi G, Riccardi G, Chiarelli LR. The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens. *Eur J Med Chem*. 2020; 190: 112132. DOI: 10.1016/j.ejmech.2020.112132.

113. Mori G, Orena BS, Chiarelli LR, Degiacomi G, **Riabova O**, Sammartino JC, **Makarov V**, Riccardi G, Pasca MR. Rv0579 is involved in the resistance to the TP053 antitubercular prodrug. *Front Microbiol.* 2020; 11: 292. DOI: 10.3389/fmicb.2020.00292.
114. **Egorova AP, Makarov VA**. WIN compounds: on the way to efficient antipicornaviral agent. A historical survey. *Russ Chem Bull.* 2020; 69: 635-646. DOI: 10.1007/s11172-020-2811-x.
115. Chiarelli LR, Scoffone VC, Trespidi G, Barbieri G, **Riabova O, Monakhova N**, Porta A, Manina G, Riccardi G, **Makarov V**, Buroni S. Chemical, metabolic, and cellular characterization of a FtsZ inhibitor effective against *Burkholderia cenocepacia*. *Front Microbiol.* 2020; 11: 562. DOI: 10.3389/fmicb.2020.00562.
116. Volobueva A, **Egorova A**, Galochkina A, Ekins S, Zarubaev V, **Makarov V**. The evolution of pleconaril: modified O-alkyl linker analogs have biological activity towards Coxsackievirus B3 Nancy. *Molecules.* 2020; 25(6): 1345. DOI: 10.3390/molecules25061345.
117. **Makarov V**, Mikušová K. Development of macozinone for TB treatment: An Update. *Appl Sci.* 2020; 10(7): 2269. DOI: 10.3390/app10072269.
118. **Makarov V**, Salina E, Reynolds RC, Kyaw Zin PP, Ekins S. Molecule property analyses of active Compounds for *Mycobacterium tuberculosis*. *J Med Chem.* 2020; 63(17): 8917-8955. DOI: 10.1021/acs.jmedchem.9b02075.
119. Székely R, Rengifo-Gonzalez M, Singh V, **Riabova O**, Benjak A, Piton J, Cimino M, Kornobis E, Mizrahi V, Johnsson K, Manina G, **Makarov V**, Cole ST. 6,11-Dioxobenzo[*f*]pyrido[1,2-*a*]indoles kill *Mycobacterium tuberculosis* by targeting iron-sulfur protein Rv0338c (IspQ), a putative redox sensor. *ACS Infect Dis.* 2020; 6(11): 3015-3025. DOI: 10.1021/acsinfecdis.0c00531.

2021

120. **Egorova A**, Bogner E, **Novoselova E**, Zorn KM, Ekins S, **Makarov V**. Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review). *Eur J Med Chem.* 2021; 211: 113014. DOI: 10.1016/j.ejmech.2020.113014.
121. Chiarelli LR, Degiacomi G, **Egorova A, Makarov V**, Pasca MR. Nitric oxide-releasing compounds for the treatment of lung infections. *Drug Discov Today.* 2021; 26(2): 542-550. DOI: 10.1016/j.drudis.2020.10.027.
122. **Monakhova N**, Korduláková J, Vocat A, **Egorova A, Lepioshkin A**, Salina EG, Nosek J, Repková E, Zemanová J, Jurdáková H, Górová R, Roh J, Degiacomi G, Sammartino JC, Pasca MR, Cole ST, Mikušová K, **Makarov V**. Design and synthesis of pyrano[3,2-*b*]indolones showing antimycobacterial activity. *ACS Infect Dis.* 2021; 7(1): 88-100. DOI: 10.1021/acsinfecdis.0c00622.
123. Adefeldt R, Schmitz J, Kropff B, Thomas M, **Monakhova N**, Hölper JE, Klupp BG, Mettenleiter TC, **Makarov V**, Bogner E. Diazadispiroalkane derivatives are new viral entry

- inhibitors. *Antimicrob Agents Chemother.* 2021; 65(4): e02103-20. DOI: 10.1128/AAC.02103-20.
124. Bogner E, **Egorova A, Makarov V**. Small molecules-prospective novel HCMV inhibitors. *Viruses.* 2021; 13(3): 474. DOI: 10.3390/v13030474.
125. **Egorova A**, Jackson M, **Gavrilyuk V, Makarov V**. Pipeline of anti-*Mycobacterium abscessus* small molecules: Repurposable drugs and promising novel chemical entities. *Med Res Rev.* 2021; 41(4): 2350-2387. DOI: 10.1002/med.21798.
126. Donlin MJ, Lane TR, **Riabova O, Lepioshkin A**, Xu E, Lin J, **Makarov V**, Ekins S. Discovery of 5-nitro-6-thiocyanatopyrimidines as inhibitors of *Cryptococcus neoformans* and *Cryptococcus gattii*. *ACS Med Chem Lett.* 2021; 12(5): 774-781. DOI: 10.1021/acsmchemlett.1c00038.
127. Gawriljuk VO, Foil DH, Puhl AC, Zorn KM, Lane TR, **Riabova O, Makarov V**, Godoy AS, Oliva G, Ekins S. Development of machine learning models and the discovery of a new antiviral compound against yellow fever virus. *J Chem Inf Model.* 2021; 61(8): 3804-3813. DOI: 10.1021/acs.jcim.1c00460.
128. Trespidi G, Scoffone VC, Barbieri G, Marchesini F, Abualsha'ar A, Coenye T, Ungaro F, **Makarov V**, Migliavacca R, De Rossi E, Buroni S. Antistaphylococcal activity of the FtsZ inhibitor C109. *Pathogens.* 2021; 10(7): 886. DOI: 10.3390/pathogens10070886.
129. **Egorova A**, Salina EG, **Makarov V**. Targeting non-replicating *Mycobacterium tuberculosis* and latent infection: alternatives and perspectives (mini-review). *Int J Mol Sci.* 2021; 22(24): 13317. DOI: 10.3390/ijms222413317.

2022

130. Lane TR, Urbina F, Rank L, Gerlach J, **Riabova O, Lepioshkin A, Kazakova E**, Vocat A, Tkachenko V, Cole S, **Makarov V**, Ekins S. Machine learning models for *Mycobacterium tuberculosis in vitro* activity: prediction and target visualization. *Mol Pharm.* 2022; 19(2): 674-689. doi: 10.1021/acs.molpharmaceut.1c00791.
131. Schmalstig AA, Zorn KM, Murcia S, Robinson A, Savina S, **Komarova E, Makarov V**, Braunstein M, Ekins S. *Mycobacterium abscessus* drug discovery using machine learning. *Tuberculosis (Edinb).* 2022; 132: 102168. doi: 10.1016/j.tube.2022.102168.
132. Gur'eva YA, Zalevskaya OA, Shevchenko OG, Slepukhin PA, **Makarov VA**, Kuchin AV. Copper(II) complexes with terpene derivatives of ethylenediamine: synthesis, and antibacterial, antifungal and antioxidant activity. *RSC Adv.* 2022; 12(15): 8841-8851. doi: 10.1039/d2ra00223j.
133. Alimbarova L, **Egorova A, Riabova O, Monakhova N, Makarov V**. A proof-of-concept study for the efficacy of dispirotriperazine PDSTP in a rabbit model of herpes simplex epithelial keratitis. *Antiviral Res.* 2022; 202: 105327. doi: 10.1016/j.antiviral.2022.105327.
134. Puhl AC, Gomes GF, Damasceno S, Godoy AS, Noske GD, Nakamura AM, Gawriljuk VO, Fernandes RS, **Monakhova N, Riabova O**, Lane TR, **Makarov V**, Veras FP, Batah SS,

- Fabro AT, Oliva G, Cunha FQ, Alves-Filho JC, Cunha TM, Ekins S. Pyronaridine protects against SARS-CoV-2 infection in mouse. *ACS Infect Dis.* 2022; 8(6): 1147-1160. doi: 10.1021/acscinfecdis.2c00091.
135. Glenn SM, Turapov O, **Makarov V**, Kell DB, Mukamolova GV. Dimethyl fumarate eliminates differentially culturable *Mycobacterium tuberculosis* in an intranasal murine model of tuberculosis. *Front Cell Infect Microbiol.* 2022; 12: 957287. doi: 10.3389/fcimb.2022.957287.
136. **Riabova O, Egorova A, Lepioshkin A**, Li Y, Voigt K, Kloss F, **Makarov V**. Thieno[2,3-*d*]pyrimidine-core compounds show activity against clinically relevant gram-positive bacteria. *ChemMedChem.* 2022; 17(17): e202200207. doi: 10.1002/cmdc.202200207.
137. Dohme A, Knoblauch M, **Egorova A, Makarov V**, Bogner E. Broad-spectrum antiviral diazadispiroalkane core molecules block attachment and cell-to-cell spread of herpesviruses. *Antiviral Res.* 2022; 206: 105402. doi: 10.1016/j.antiviral.2022.105402.
138. **Makarov VA**, Popov VO. PDSTP is the first drug in class to treat coronavirus infection. *Her Russ Acad Sci.* 2022; 92(4): 488-490. doi: 10.1134/S1019331622040190.
139. Rank L, Puhl AC, Havener TM, Anderson E, Foil DH, Zorn KM, **Monakhova N, Riabova O**, Hickey AJ, **Makarov V**, Ekins S. Multiple approaches to repurposing drugs for neuroblastoma. *Bioorg Med Chem.* 2022; 73: 117043. doi: 10.1016/j.bmc.2022.117043.
140. Degiacomi G, **Makarov V**, Pasca MR, Chiarelli LR. New drugs and novel cellular targets against tuberculosis. *Int J Mol Sci.* 2022; 23(22): 13680. doi: 10.3390/ijms232213680.
141. Scoffone VC, Irudal S, Alshaar A, Piazza A, Trespidi G, Barbieri G, **Makarov V**, Migliavacca R, De Rossi E, Buroni S. Bactericidal and anti-biofilm activity of the FtsZ inhibitor C109 against *Acinetobacter baumannii*. *Antibiotics.* 2022; 11(11): 1571. doi: 10.3390/antibiotics11111571.
142. Salina EG, Postiglione U, Chiarelli LR, Recchia D, Záhorszská M, **Lepioshkin A, Monakhova N**, Pál A, Porta A, Zaroni G, Korduláková J, Kazakova E, Sassera D, Pasca MR, **Makarov V**, Degiacomi G. A new benzothiazolthiazolidine derivative, 11726172, is active *in vitro*, *in vivo*, and against nonreplicating cells of *Mycobacterium tuberculosis*. *mSphere.* 2022: e0036922. doi: 10.1128/msphere.00369-22.
143. Salina EG, **Makarov V**. *Mycobacterium tuberculosis* dormancy: how to fight a hidden danger. *Microorganisms*, 2022, 10(12), 2334. doi: 10.3390/microorganisms10122334.

2023

144. Desfontaine V, Guinchard S, Marques S, Vocat A, Moulfi F, Versace F, Huser-Pitteloud J, Ivanyuk A, Bardinnet C, **Makarov V, Ryabova O**, André P, Prod'Hom S, Chtioui H, Buclin T, Cole ST, Decosterd L. Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer complex and other metabolites, in human plasma and urine. *J Chromatogr B.* 2023; 1215: 123555. doi: 10.1016/j.jchromb.2022.123555.

145. Koryakova A, Shcherbakova V, **Riabova O**, Kazaishvili Y, Bolgarin R, **Makarov V**. Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs. *Microbiol Spectr*. 2023; 11(1): e0232722. doi: 10.1128/spectrum.02327-22.
146. Lane T, **Makarov V**, Nelson JAE, Meeker RB, Sanna G, **Riabova O**, **Kazakova E**, **Monakhova N**, Tsedilin A, Urbina F, Jones T, Suchy A, Ekins S. *N*-Phenyl-1-(phenylsulfonyl)-1*H*-1,2,4-triazol-3-amine as a new class of HIV-1 non-nucleoside reverse transcriptase inhibitor. *J Med Chem*. 2023; 66(9): 6193-6217. doi: 10.1021/acs.jmedchem.2c02055.
147. Lane TR, Fu J, Sherry B, Tarbet B, Hurst BL, **Riabova O**, **Kazakova E**, **Egorova A**, Clarke P, Leser JS, Frost J, Rudy M, Tyler KL, Klose T, Volobueva AS, Belyaevskaya SV, Zarubaev VV, Kuhn RJ, **Makarov V**, Ekins S. Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5. *Antiviral Res*. 2023; 216: 105654. doi: 10.1016/j.antiviral.2023.105654.
148. **Egorova A**, Richter M, Khrenova M, Dietrich E, Tsedilin A, **Kazakova E**, **Lepioshkin A**, Jahn B, Chernyshev V, Schmidtke M, **Makarov V**. Pyrrolo[2,3-*e*]indazole as a novel chemotype for both influenza A virus and pneumococcal neuraminidase inhibitors. *RSC Adv*. 2023; 13(27): 18253-18261. doi: 10.1039/d3ra02895j.
149. Degiacomi G, Gianibbi B, Recchia D, Stelitano G, Truglio GI, Marra P, Stamilla A, **Makarov V**, Chiarelli LR, Manetti F, Pasca MR. CanB, a druggable cellular target in *Mycobacterium tuberculosis*. *ACS Omega*. 2023; 8(28): 25209-25220. doi: 10.1021/acsomega.3c02311.
150. Fan D, Wang B, Stelitano G, Savková K, **Riabova O**, Shi R, Wu X, Chiarelli LR, Mikušová K, **Makarov V**, Lu Y, Hong Y, Qiao C. Side chain-modified benzothiazinone derivatives with anti-mycobacterial activity. *Biomedicines*. 2023; 11(7): 1975. doi: 10.3390/biomedicines11071975.
151. Jones T, Tavis JE, Li Q, **Riabova O**, **Monakhova N**, Bradley DP, Lane TR, **Makarov V**, Ekins S. Antiviral evaluation of dispirotriperazines against hepatitis B virus. *J Med Chem*. 2023; 66(17): 12459-12467. doi: 10.1021/acs.jmedchem.3c00974.

ПАТЕНТЫ

1. WO 2003042186. Möllmann U, **Makarov VA**. Dithiocarbamate derivatives and their use as antibacterial agents.
2. DE 10350929. Bockmühl D, Boy J, Weide M, Heinzl M, Breves R, Eck R, Künkel W, Möllmann U, **Makarov V**. Use of dispirotriperazine derivatives to treat fungal infections or to prevent adhesion of fungi to surfaces.
3. WO 2007134625. **Makarov VA**, Cole ST, Möllmann U. New benzothiazinone derivatives and their use as antibacterial agents.

3. WO 2007147401. **Makarov V**, Wutzler P, Schmidtke M, Dahse HM. 4-Amino-3-aryl-amino-6-arylpyrazolo[3,4-*d*]pyrimidine derivatives, methods of their preparation and use as antiviral agents.
4. RU 2312104. Nemeryuk MP, Sedov AL, **Makarov VA**, Safonova TS, Abelentsev VI, Zaikin B. 4-Methoxy-5-nitro-6-thiocyanopyrimidine possessing fungicide activity and method for its preparing.
5. WO 2009010163. Möllmann U, **Makarov V**, Stewart CT. New antimicrobial compounds, their synthesis and their use for treatment of mammalian infections.
6. WO 2012066518. **Makarov V**, Stewart C. 2-Piperazin-1-yl-4*H*-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections. EP 2 640 712 B1 /
7. WO 2011132070. **Makarov VA**. Process for the preparation of 2-amino-substituted 1,3-benzothiazine-4-ones.
9. WO 2013053942. Wutzler P, Schmidtke M, **Makarov V**. 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-*d*]pyrimidine derivatives, their manufacture and their use as antiviral active substances.
10. RU 2487132. **Макаров ВА**, Суровцев ВВ. Производные циклических 5-нитропиридин-2-ил-тиоалкенил-4-дитиокарбаматов, обладающие противогрибковой активностью, и их применение
11. RU 2566818. **Макаров ВА**. Способ получения (\pm)*N*-[1-(4-фторфенил)-2-(1-этилпиперидин-4-ил)этил]-4-нитробензамида или его фармацевтически приемлемых солей и промежуточное соединение для его получения.
12. WO 2015167368. **Makarov VA, Monakhova NS, Riabova OB**. 4,6-Di(3,12-diaza-6,9-diazoniadispiro[5.2.5.2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate for the treatment of herpetic infection and a topical pharmaceutical composition.
13. WO 2016151011. Stewart C, **Makarov VA**. 2-Homopiperazine-1-yl-4*H*-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides.
14. WO 2017069661. **Makarov VA**, Nesterenko VG, Bolgarin RN, Novoselova EA. Pyrimidyl-di(diazaspiro-alkanes) with antiviral activity.
15. RU 2675240. **Макаров ВА, Лепешкин АЮ, Монахова НС**, Салина ЕГ. Пираноиндолы с противотуберкулезной активностью.
16. RU 2756587. **Макаров ВА**, Зарубаев ВВ. Производные 2-ацетиамидо-6-гидроксибензотиофена и их фармацевтически приемлемые соли, обладающие противовирусной активностью.